Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana (IHS)
Multicenter Research Study to Build a Repository That Will Allow Researchers to Study Chronic Diseases in the Population of Central Indiana
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Study Aim:
The purpose of this study is to create an extensively annotated bio-repository platform for hypothesis-driven research that will lead to advancements in the diagnosis, treatment and prevention of diseases common to the population of Indiana. The second phase of this research platform will be created by collecting blood samples from two groups of individuals in the Central Indiana community, one with documented evidence of Diabetes Mellitus Type II(T2D), and a second group of age, gender and ethnicity matched individuals without clinical evidence of Diabetes. Each individual's blood sample will be linked to their clinical, demographic and epidemiological information, gathered both retrospectively and prospectively.
Recruitment:
This study will include 500 individuals with T2D (the T2D Group) and 500 individuals who are age, gender, and ethnicity matched to the T2D Group, but without presentation of clinical evidence of T2D (the Control Group). To reflect the growing representation of Hispanics in Central Indiana, Hispanics will be overly recruited in both groups so that the study population accurately reflects the general population of Central Indiana.
Follow-up:
As this is a prospective, longitudinal study, follow-up of study subjects is intended to include two follow up visit and continue indefinitely, unless, of course, at any time, consent for further follow-up is withdrawn by the subject. Follow-up will include visits at 2 and 5 years post initial contact and continuing access to the subject's medical record to pursue data concerning changes in the subject's health. Subjects may be contacted by telephone, mail or email every twelve months to ask if they wish to continue participation in the study. The 2 and 5 year follow up visits mirror the initial visit.
The collected dataset (made up of the collected blood samples linked to clinical and epidemiological information collected retrospectively and prospectively), will be used in medical research to find genes, or gene products such as RNA or proteins that will help in understanding the causes of disease and will guide the development of new treatments
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Indiana
-
Avon, Indiana, Estados Unidos
- American Health Network
-
Brownsburg, Indiana, Estados Unidos
- Investigator's Research Group
-
Franklin, Indiana, Estados Unidos
- American Health Network
-
Greenfield, Indiana, Estados Unidos
- American Health Network
-
Indianapolis, Indiana, Estados Unidos
- American Health Network
-
Indianapolis, Indiana, Estados Unidos
- Krannert Cardiology
-
Indianapolis, Indiana, Estados Unidos
- Oral Health Research Institute
-
Indianapolis (Downtown), Indiana, Estados Unidos
- IU School of Medicine/CTSI
-
Indianapolis (Spanish speaking), Indiana, Estados Unidos
- Alivio Medical Center
-
Indianapolis (Spanish/English speaking), Indiana, Estados Unidos
- IU Medical Group
-
Muncie, Indiana, Estados Unidos
- American Health Network
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:T2D Group
Study subjects will be recruited for the T2D group based on a history confirmed by the medical record of at least one of the following:
- A fasting blood glucose of greater than or equal to 126 mg/dL on two separate occasions
- A random (non-fasting) blood glucose of greater than or equal to 200 mg/dL on two separate occasions
- A blood glucose of greater than 200 mg/dL at 2 hours during a standard oral glucose tolerance test
- A HgbA1c of greater than or equal to 6.5%
Females who are pregnant will be excluded.
Control Group
Study subjects for the Control Group will have:
- no confirmed history of T2D as defined above
- A fasting blood glucose of 100 mg/dL or less
Medical records will be obtained to ensure subjects meet study inclusion criteria.
-
Exclusion Criteria:Exclusion criteria for both the T2D Group and the Control Group are a known or reported history of:
- Hepatitis B
- Hepatitis C
- AIDS (HIV positive)
- Tuberculosis
- Cancer (including melanoma, but excluding low-malignancy skin cancer)
- Non-autologous bone marrow transplant
- Blood transfusion within 120 days
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
People with Diabetes Mellitus Type II
500 subjects will have T2D
|
|
Healthy
500 persons who do not have T2D, hypertension or hypercholesterol
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Anantha Shekhar, MD, Indiana University School of Medine/CTSI
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- FIHC-2009-01
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .